Tempest Therapeutics (NASDAQ:TPST) Releases Earnings Results, Meets Expectations

Tempest Therapeutics (NASDAQ:TPST) issued its quarterly earnings results on Monday. The company reported ($0.62) EPS for the quarter, meeting analysts’ consensus estimates of ($0.62), FiscalAI reports.

Tempest Therapeutics Price Performance

Shares of NASDAQ:TPST opened at $1.64 on Wednesday. The company’s 50-day moving average price is $2.33 and its two-hundred day moving average price is $5.14. Tempest Therapeutics has a one year low of $1.50 and a one year high of $12.23. The stock has a market capitalization of $8.09 million, a PE ratio of -0.25 and a beta of -2.42.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempest Therapeutics currently has an average rating of “Reduce” and an average price target of $12.50.

Insider Buying and Selling at Tempest Therapeutics

In related news, CEO Matthew Angel acquired 231,482 shares of the firm’s stock in a transaction dated Tuesday, March 24th. The stock was bought at an average price of $2.16 per share, for a total transaction of $500,001.12. Following the acquisition, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.28% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. grew its stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 162,560 shares of the company’s stock after purchasing an additional 27,952 shares during the quarter. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.